Banarian Nordic Res (BVNKF) 29.0400 $BVNKF
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Tue Jan 27, 12:57AM CST
KVISTGAARD, Denmark, January 27, 2015 - Bavarian Nordic A/S (OMX: BAVA) has received information from A. J. Aamund A/S that the company has sold 1,793,944 shares in Bavarian Nordic and thus no longer holds any shares and voting rights in Bavarian Nordic.
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 99.62 (+1.18)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
Bavarian Nordic Announces First Subject Dosed with MVA-BN(R) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
Thomson Reuters ONE - Thu Dec 04, 12:31AM CST
- First human trial investigating MVA-BN(R) Filo as an Ebola vaccine
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue Nov 18, 3:21AM CST
KVISTGAARD, Denmark, November 18, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 1,217,500 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 275,665,970.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014
Thomson Reuters ONE - Thu Nov 13, 12:42AM CST
KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014.
Bavarian Nordic to Host Third Quarter 2014 Results Conference Call
Thomson Reuters ONE - Thu Nov 06, 10:30AM CST
KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 29, 4:15AM CDT
Summary: Bavarian Nordic increases its share capital by nominally DKK 13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct placement to Johnson & Johnson Development Corporation ("JJDC"
in connection with the license and supply agreement for the Company's MVA-BN(R) vector in respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson.
JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets
Thomson Reuters ONE - Wed Oct 22, 4:47PM CDT
KVISTGAARD, Denmark, October 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets.
JNJ: 99.62 (+1.18)
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
GlobeNewswire - Wed Oct 22, 1:06AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Additional Details Concerning the Issue of Shares to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 22, 12:56AM CDT
Summary: Further details on the placement of Bavarian Nordic shares to Johnson & Johnson Development Corporation ("J&J" in connection with an agreement for co-development and commercialization of the Company's MVA-BN(R) vector in respect of Ebola. J&J will subscribe for Bavarian Nordic shares in the amount of DKK 251,000,000. However, Bavarian Nordic will issue a maximum of 1,673,333 shares of DKK 10 each (equal to approximately 6.4 per cent of the existing share capital of the Company). The number of subscribed shares may be lower than 1,673,333 shares depending on the final subscription price. The new shares will be subscribed for in cash at the market price which is based on the simple average of the volume weighted average price of the Company's shares on Nasdaq Copenhagen ("Nasdaq" (Bloomberg VWAP for BAVA.DC, referred to as "VWAP" during a period of five consecutive trading days starting on 22 October 2014, subject to a minimum subscription price of DKK 150 per share of DKK 10 corresponding to the closing price of the Company's shares on Nasdaq on 21 October 2014.
JNJ: 99.62 (+1.18)
Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE(r) Smallpox Vaccine
GlobeNewswire - Thu Sep 04, 11:19AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health & Human Services (HHS) has exercised an option valued at USD 118 million for the continued delivery of IMVAMUNE smallpox vaccine to the U.S. Strategic National Stockpile (SNS).
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Tue Jan 27, 12:57AM CST
KVISTGAARD, Denmark, January 27, 2015 - Bavarian Nordic A/S (OMX: BAVA) has received information from A. J. Aamund A/S that the company has sold 1,793,944 shares in Bavarian Nordic and thus no longer holds any shares and voting rights in Bavarian Nordic.
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 99.62 (+1.18)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
Bavarian Nordic Announces First Subject Dosed with MVA-BN(R) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
Thomson Reuters ONE - Thu Dec 04, 12:31AM CST
- First human trial investigating MVA-BN(R) Filo as an Ebola vaccine
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue Nov 18, 3:21AM CST
KVISTGAARD, Denmark, November 18, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 1,217,500 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 275,665,970.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014
Thomson Reuters ONE - Thu Nov 13, 12:42AM CST
KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014.
Bavarian Nordic to Host Third Quarter 2014 Results Conference Call
Thomson Reuters ONE - Thu Nov 06, 10:30AM CST
KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 29, 4:15AM CDT
Summary: Bavarian Nordic increases its share capital by nominally DKK 13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct placement to Johnson & Johnson Development Corporation ("JJDC"
in connection with the license and supply agreement for the Company's MVA-BN(R) vector in respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson. JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets
Thomson Reuters ONE - Wed Oct 22, 4:47PM CDT
KVISTGAARD, Denmark, October 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets.
JNJ: 99.62 (+1.18)
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
GlobeNewswire - Wed Oct 22, 1:06AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JNJ: 99.62 (+1.18)
Bavarian Nordic Announces Additional Details Concerning the Issue of Shares to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 22, 12:56AM CDT
Summary: Further details on the placement of Bavarian Nordic shares to Johnson & Johnson Development Corporation ("J&J"
in connection with an agreement for co-development and commercialization of the Company's MVA-BN(R) vector in respect of Ebola. J&J will subscribe for Bavarian Nordic shares in the amount of DKK 251,000,000. However, Bavarian Nordic will issue a maximum of 1,673,333 shares of DKK 10 each (equal to approximately 6.4 per cent of the existing share capital of the Company). The number of subscribed shares may be lower than 1,673,333 shares depending on the final subscription price. The new shares will be subscribed for in cash at the market price which is based on the simple average of the volume weighted average price of the Company's shares on Nasdaq Copenhagen ("Nasdaq" (Bloomberg VWAP for BAVA.DC, referred to as "VWAP" during a period of five consecutive trading days starting on 22 October 2014, subject to a minimum subscription price of DKK 150 per share of DKK 10 corresponding to the closing price of the Company's shares on Nasdaq on 21 October 2014. JNJ: 99.62 (+1.18)
Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE(r) Smallpox Vaccine
GlobeNewswire - Thu Sep 04, 11:19AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health & Human Services (HHS) has exercised an option valued at USD 118 million for the continued delivery of IMVAMUNE smallpox vaccine to the U.S. Strategic National Stockpile (SNS).
